Abbvie inc.ABBV.US Overview
ABBV Overall Performance
ABBV AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ABBV Current Performance
0.54%
Abbvie inc.
-0.58%
Avg of Sector
0.83%
S&P500
ABBV Key Information
ABBV Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ABBV Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ABBV Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Price of ABBV
ABBV FAQ
When is ABBV's latest earnings report released?
The most recent financial report for Abbvie inc. (ABBV) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABBV's short-term business performance and financial health. For the latest updates on ABBV's earnings releases, visit this page regularly.
Where does ABBV fall in the P/E River chart?
According to historical valuation range analysis, Abbvie inc. (ABBV)'s current price-to-earnings (P/E) ratio is 92.57, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of ABBV?
According to the latest financial report, Abbvie inc. (ABBV) reported an Operating Profit of 4.89B with an Operating Margin of 31.73% this period, representing a growth of 22.41% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ABBV's revenue growth?
In the latest financial report, Abbvie inc. (ABBV) announced revenue of 15.42B, with a Year-Over-Year growth rate of 6.65%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ABBV have?
As of the end of the reporting period, Abbvie inc. (ABBV) had total debt of 70.48B, with a debt ratio of 0.51. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ABBV have?
At the end of the period, Abbvie inc. (ABBV) held Total Cash and Cash Equivalents of 6.47B, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ABBV go with three margins increasing?
In the latest report, Abbvie inc. (ABBV) achieved the “three margins increasing” benchmark, with a gross margin of 71.8%%, operating margin of 31.73%%, and net margin of 6.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ABBV's profit trajectory and future growth potential.
Is ABBV's EPS continuing to grow?
According to the past four quarterly reports, Abbvie inc. (ABBV)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.52. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ABBV?
Abbvie inc. (ABBV)'s Free Cash Flow (FCF) for the period is 4.88B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 140.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ABBV?
The latest valuation data shows Abbvie inc. (ABBV) has a Price-To-Earnings (PE) ratio of 92.57 and a Price/Earnings-To-Growth (PEG) ratio of -3.3. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.